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Introduction
Recently, traditional Chinese medicine (called Kampo medi-
cine in Japan) has been recognized once again for its efficacy
and there has been a noticeable increase in its popularity around
the world (1) because of its supposedly less frequent side
effects (2). One of the main characteristics of traditional medi-
cine is that it has been developed through experience passed
on from one generation to another. In other words, traditional
medicine emphasizes subjective symptoms, while Western
medicine emphasizes objective findings (i.e., practitioners of
traditional medicine do not easily lend themselves to random-
ized, double-blind, placebo-controlled trials). Consequently,
despite a long history of application of traditional medicine,
scientific evidences about its effects have been superficial. On
the other hand, the requirement for scientific validation of the
ancient wisdom (the Kampo medicine) from the clinical front
has increased markedly.
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Previous studies have shown that the traditional herbal complex Gosha-jinki-gan (GJG) improves diabetic
neuropathy and insulin resistance. The present study was undertaken to elucidate the molecular mecha-
nisms related with the long-term effects of GJG administration on insulin action in vivo and the early steps
of insulin signaling in skeletal muscle in streptozotocin (STZ) diabetes. Rats were randomized into five
subgroups: (1) saline treated control, (2) GJG treated control, (3) 2-unit insulin   saline treated diabetic,
(4) saline   GJG treated diabetic and (5) 2-unit insulin   GJG treated diabetic groups. After seven days
of treatment, euglycemic clamp experiment at an insulin infusion rate of 6 mU/kg/min was performed in
overnight fasted rats. Despite the 2-unit insulin treatment, the metabolic clearance rates of glucose (MCR,
ml/kg/min) in diabetic rats were significantly lower compared with the controls (11.4   1.0 vs 44.1   1.5;
P   0.001), and were significantly improved by insulin combined with GJG or GJG alone (26   3.2 and
24.6   2.2, P   0.01, respectively). The increased insulin receptor (IR)-  protein content in skeletal mus-
cle of diabetic rats was not affected by insulin combined with GJG administration. However, the decreased
insulin receptor substrate-1 (IRS-1) protein content was significantly improved by treatment with GJG.
Additionally, the increased tyrosine phosphorylation levels of IR-  and IRS-1 were significantly inhibited
in insulin combined with GJG treated diabetes. The present results suggest that the improvement of the
impaired insulin sensitivity in STZ-diabetic rats by administration of GJG may be due, at least in part, to
correction in the abnormal early steps of insulin signaling in skeletal muscle.
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derivative work this must be clearly indicated.Streptozotocin (STZ)-induced diabetic rats are thought to be
good models of type 1 diabetes mellitus with insulin deficiency
and insulin resistance as metabolic characteristics. However, in
this model of diabetes, the impaired insulin-stimulated skeletal
muscle glucose metabolism and transporter translocation cannot
be restored to normal levels despite insulin therapy (3), and this
is concordant with human type 1 diabetes (4,5). It is considered
that insulin therapy cannot correct the altered insulin signaling
mechanism in diabetic skeletal muscle and consequently, cannot
normalize the glucose transport system (6). Furthermore, the
precise mechanism may involve abnormalities in the content
and/or tyrosine phosphorylation of insulin signaling proteins in
STZ-diabetic skeletal muscle (7,8), expressing a decreased effi-
ciency of glucose metabolism (8,9). In any case, alterations in
the early steps of insulin signaling have been recognized as an
important component in several insulin-resistant states.
Gosha-jinki-gan (GJG), a traditional herbal combined
prescription composed of 10 crude herbs (Table 1), has been
described as being useful in the treatment of many subjective
symptoms, including fatigability, cold in the extremities, leg
numbness and pain, copious urine with thirst, cloudy vision in
old age and lumbago (10). GJG is considered to be a useful
approach for the improvement of subjective symptoms such as
numbness (11–13), sensation of cold (11,12) and pain in the
extremities (13) associated with diabetic neuropathy. Some
evidences suggest that GJG administration has a vasodilating
(14,15) and antinociceptive effect (16), improving the insulin
resistance (17) in STZ-diabetes as a result of increased nitric
oxide (NO) production. However, the molecular mechanisms
associated with these GJG effects are still not clarified ade-
quately. Therefore, the present study was undertaken firstly to
determine the long-term effects of insulin injection combined
with GJG administration on the insulin sensitivity in STZ-
induced diabetic rats. Our second objective was to investigate
whether it is true that GJG treatment potentiates the insulin
action, by means of an insulin tolerance test. We further studied
the molecular effect of combined GJG administration on the
early steps of the insulin-signaling pathway in skeletal muscle.
Materials and Methods
STZ was purchased from Sigma (St. Louis, MO, USA) and
neutral insulin from Novo Nordisk (Copenhagen, Denmark).
Anti-insulin receptor (IR)- , anti-insulin receptor substrate
(IRS)-1 antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Hyperfilm was purchased
from Amersham (Little Chalfont, Buckinghamshire, UK). All
other reagents were of biochemical grade. Herbal extract of
GJG was kindly provided by Tsumura Co. (Tokyo, Japan).
Experimental Animals, Diabetes Induction
Male Wistar rats (n   42) aged 8 weeks (220–230 g) were pur-
chased form CLEA (Shizuoka, Japan). The rats were housed
in a room maintained at constant humidity (60   5%), tempera-
ture (23   1  C), and a 12-h light/dark cycle (lighting from
8:00 to 20:00). The standard diet obtained from Oriental Yeast
Co. Ltd., (Chiba, Japan) and tap water were available ad 
libitum throughout the study. All experimental procedures were
approved by and carried out in accordance with the guidelines
of Nagoya University for the care and use of laboratory animals
(detailed procedures are shown in Fig. 1). After a one-week
acclimatization period, the rats were divided into two groups
and one group was rendered diabetic with a single STZ injec-
tion from the tail vein as previously described (18); control rats
were only administered citrate buffer. Animals with postpran-
dial blood glucose levels greater than 300 mg/dl 3 days after
STZ injection were considered diabetic. After 1 day of recov-
ery from STZ treatment, 2 units of insulin, enough to prevent
ketosis but not enough to normalize hyperglycemia (19), were
subcutaneously injected between 9:00 h~10:00 h daily in the
diabetic rats. Thereafter, the rats were further randomized into
five subgroups: (1) saline treated control, (2) GJG treated con-
trol, (3) insulin   saline treated diabetic, (4) saline   GJG
treated diabetic and (5) insulin   GJG treated diabetic groups.
Surgical Procedures
Three days after STZ treatment, the animals were anesthetized
with sodium pentobarbital (50 mg/kg) and the surgical proce-
dures were performed as described in our previous reports
(18,20). During the clamp study, jugular and femoral catheters
were used for blood sampling and insulin and/or glucose
infusion, respectively.
Exogenous Insulin and GJG Administration
The medicine administration was started one night after surgery.
In the insulin treated groups, the dose of ultralente insulin was
not changed. The GJG, dissolved in 5 ml/kg saline, was injected
through a gastric tube once a day, and the dose of GJG was
800 mg/kg BW, according to a previous study (17); the remaining
rats were administered only saline. In the saline   GJG treated
diabetic group, insulin injection was replaced by saline. The rats
were administered these treatments for 1 week and then sub-
jected to the euglycemic clamp study after overnight fasting.
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Table 1. Composition of GJG
Component %
Rehmanniae Radix 17.9
Achyranthis Radix 10.7
Coprni Fructus 10.7
Dioscoreae Rhizoma 10.7
Plantaginis Semen 10.7
Alismatis Rhizoma 10.7
Hoclen 10.7
Moutan Cortex 10.7
Cinnamomi Cortex 3.6
Aconiti Tuber 3.6
The GJG used in this study was an unprepared bulk powder.Euglycemic Clamp Study
The clamp studies were undertaken in the morning after an
overnight fast (about 12 h). The euglycemic clamp was per-
formed as previously described (18). Briefly, 6.0 mU/kg/min
insulin was continuously infused, the blood glucose concentra-
tions of diabetic rats were lowered to 140 mg/dl, and then
clamped at this concentration by periodic adjustment of the
glucose infusion rate. The blood glucose concentrations were
measured every 10 min and the euglycemia of diabetic and
normal rats was maintained at around 139   7 and 70   4 mg/dl,
respectively. The glucose infusion rate (GIR) was calculated
every 10 min during the clamp study. The metabolic clearance
rate for glucose (MCR, ml/kg/min) was then obtained from GIR
by dividing it with the corresponding blood glucose concentra-
tion. The MCRs from 60 to 90 min for the euglycemic clamp
were regarded as indices of insulin action in peripheral tissues,
since a plateau in the glucose infusion rate was achieved during
this period, as reported previously (18). After the euglycemic
clamp study, the rats were anesthetized and the gastrocnemius
muscles were excised, immediately freeze-clamped at the liquid
nitrogen temperature and stored at  80 C until analyses.
Insulin Tolerance Test
An insulin tolerance test was performed on half of the insulin
treated and insulin   GJG treated diabetic rats (six rats in each
group). Food was withdrawn at 9:00 h~10:00 h, following
which the diabetic rats were injected with 2 units of insulin;
blood samples were drawn from the tail vein at  10, 0, 30, 60
and 120 min for glucose concentration measurements.
Analysis of the Total Protein Amount of IR-  and IRS-1
The expression of the insulin-signaling proteins in skeletal mus-
cle was measured using the Western blotting method, as previ-
ously described (18, 21). Briefly, frozen samples were
homogenized using a Polytron homogenizer, following which
the homogenates were maintained at the ice temperature and
centrifuged at 38 000 rpm at 4 C for 1 h. Supernatant proteins
(40 mg) of each sample were size-fractionated by SDS-PAGE
and then transferred to PVDF membranes. The membranes were
then incubated overnight with anti-IR  and anti-IRS-1 antibod-
ies at 4 C. Bound antibodies were detected by incubation with
Goat Anti-Rabbit IgG for 1 h at room temperature. After wash-
ing, blotted proteins were visualized using the enhanced chemi-
luminescence detection system (ECL Plus, Amersham).
Quantification of the band intensity on the Hyperfilm was per-
formed using the public domain NIH image software.
Immunoprecipitation and Western Blotting Analysis of
IR-  and IRS-1 Tyrosine Phosphorylation
The supernatants containing equal amounts of protein 
(1 mg/ml for each tube) were incubated overnight at 4 C with
anti-IR-  (5 mg/ml) or anti-IRS-1 (5 mg/ml), and then with 
20  l of protein A agarose beads at 4 C for 4 h. The immune
complexes were washed according to the procedure described
by others (22). Samples were re-suspended in treatment buffer
with  -mercaptoethanol and boiled for 5 min. Phosphorylated
proteins were separated by SDS-PAGE and the membranes con-
taining bound proteins were incubated with anti-phosphotyrosine
antibody. Phosphorylated proteins were visualized by the same
method described above.
Blood Assays
Blood glucose concentration was determined using a glucose
analyzer (model 2300; Yellow Springs Instrument, OH, USA).
Plasma insulin was assayed with a radioimmunoassay kit
(Phadesepa Insulin RIA, Pharmacia AB, Sweden).
Statistical Analysis
All values are expressed as means   SE. Data were analyzed by
the one-way analysis of variance. When a significant difference
was found (P   0.05), the results were further compared with
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Figure 1. Timetable for the experimental procedures. The number of rats is shown in parentheses. Surgical procedures (#) were performed 3 days after STZ
treatment.the Fisher’s PLSD test. The StatView 5.0 software (SAS
Institute Inc., Cary, NC) was used for statistical analysis.
Results
Body Weight, Blood Glucose and Plasma Insulin Levels
The body weight, blood glucose and plasma insulin levels
before and immediately after the euglycemic clamp are shown
in Table 2. Body weight and basic plasma insulin levels were
significantly lower in diabetic rats compared with the controls.
Seven days of treatment with GJG did not affect the body
weight and insulin levels throughout the experimental period.
The blood glucose levels in the 7 days GJG-treated diabetes
tended to be lower than those of saline-treated diabetes, but not
significantly. During the clamp studies, steady state plasma
insulin concentrations were not significantly different among
all experimental groups.
Effect of 7 Days Administration of Insulin Combined
with GJG on MCRs
During the clamp studies, the MCRs of diabetic rats that 
were administered insulin   saline were significantly lower
(11.4   1.5 ml/kg/min) compared with control animals (44.1  
1.0 ml/kg/min; P   0.001). In contrast, diabetic rats subjected to
7 days of GJG administration with and without insulin injection
showed significantly higher MCRs (26.1   3.2 ml/kg/min and
23.1   2.0 ml/kg/min, respectively, as shown in Fig. 2). The
MCR in the only GJG-treated diabetic rats did not reach the levels
of the insulin   GJG-treated diabetic rats; however, there was no
significant difference between these groups. No effects of GJG
treatment were seen on the MCRs of normal rats.
Effect of Administration of Insulin Combined with 
GJG During the Insulin Tolerance Test
At the 120 min time point of the insulin tolerance test, the
average blood glucose of the 2-unit insulin   GJG-treated
group was significantly lower than the 2-unit insulin injection
only group (90   24 vs 167   43 mg/dl; Fig. 3). The results of
the insulin tolerance test suggested that GJG administration
significantly potentiates the impaired insulin action, decreas-
ing the hyperglycemia of diabetic rats. The results agreed with
the above data in which GJG administration improved the
insulin-regulated glucose uptake in STZ-diabetes.
Effects of Administration of Insulin Combined with GJG
on IR-  and IRS-1 Protein Contents in Skeletal Muscle
The total amount of skeletal muscle IR-  protein (Fig. 4A)
was significantly increased in diabetic rats compared with con-
trol (128% of control, P   0.05). GJG administration did not
correct the abnormal protein content of IR- . In contrast, the
IRS-1 protein (Fig. 5A) was significantly decreased in insulin-
treated diabetes compared with control (47% of control,
P   0.001). However, it was increased to 65% of the level
observed in control by insulin injection   GJG administration.
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Table 2. Body weight and concentrations of blood glucose and plasma insulin before and after the euglycemic clamp procedure
at 6.0 mU/kg/min insulin infusion
Group Body wt (g) Glucose (mg/dl) Insulin (mU/ml)
Basic During clamp Basic During clamp 
(90 min) (90 min)
Non-diabetic
Saline (6) 223   56 7   16 9   2 8.1   0.3 103   5
GJG (6) 230   77 0   27 1   3 7.9   0.4 100   4
Diabetic
Insulin   saline (6) 200   5 190   18** 137   3 4.0   0.1* 99   6
Saline   GJG (6) 204   6 185   20** 135   4 4.1   0.2* 102   10
GJG   Insulin (6) 203   7 178   23** 131   5 4.2   0.2* 106   9
Values are means   SE. *P   0.05 vs normal control; **P   0.001 vs normal control.
Figure 2. MCRs during the euglycemic clamp procedure in normal and dia-
betic rats (insulin   saline; insulin   GJG; saline   GJG). Data are expressed
as the means   SE for six rats in each group. *P   0.01 vs insulin   GJG-
treated and saline   GJG-treated diabetic. **P   0.001 vs all diabetic groups.eCAM 2004;1(3) 273
Figure 3. Insulin tolerance test: blood glucose levels
of the insulin   GJG-treated diabetic group tended
to be lower than insulin-treated diabetic group at the
0 min time point, but not significantly. At the 120 min
time point, the average blood glucose of the
insulin   GJG-treated group was significantly lower
than the only insulin injection group. Data are
expressed as the means   SE for six rats in each
group. *P   0.05.
Figure 4. IR-  protein content (A) and tyrosine
phosphorylation levels (B) in the gastrocnemius muscle.
IP, Immunoprecipitation; IB, Immunoblotting; Ty,
Phosphotyrosine. Data are expressed as the means   SE
for five rats in each group. *P   0.05 vs insulin  saline-
treated and insulin   GJG-treated diabetic. **P   0.05
vs controls and insulin   GJG-treated diabetic.
Figure 5. IRS-1 protein content (A) and tyrosine
phosphorylation levels (B) in gastrocnemius muscle.
IP, Immunoprecipitation; IB, Immunoblotting; Ty,
Phosphotyrosine. Data are expressed as the means   SE
for five rats in each group. *P   0.05 vs insulin  
GJG-treated diabetic. **P   0.001 vs all diabetic groups.Effects of Administration of Insulin Combined with
GJG on the Tyrosine Phosphorylation of IR-  and
IRS-1 in Skeletal Muscle
The tyrosine phosphorylation level of IR-  was determined
by immunoblotting the IR-  antibody immunoprecipitates with
the phosphotyrosine antibody. As shown in Fig. 4B, the tyro-
sine phosphorylation level of IR-  in skeletal muscle of STZ-
diabetes was significantly increased when compared with
control (140% of control, P   0.05). The overexpressed tyro-
sine phosphorylation of IR-  was corrected by GJG treatment.
The same trend was found in IRS-1 tyrosine phosphorylation.
As shown in Fig. 5B, the abnormal increases in IRS-1 tyrosine
phosphorylation induced by STZ (137% of control, P   0.05)
was just about reversed by GJG treatment.
Discussion
In the present study, we investigated the long-term effects of
GJG combined with a small dose of exogenous insulin on the
impaired insulin action of STZ-diabetes. The results of the
euglycemic clamp study suggested that the insulin action was
significantly impaired by STZ treatment, despite the injection
of 2 units of insulin. However, the impaired insulin sensitivity
was significantly improved by 7 days administration of insulin
combined with GJG or GJG alone. The results were in agree-
ment with the insulin tolerance test, i.e., GJG administration
potentiates the action of exogenously administered insulin,
which results in decreased hyperglycemia in STZ-diabetes.
Although GJG administration was shown to significantly
potentiate the impaired insulin action, 7 days of GJG adminis-
tration did not significantly decrease the fasting blood glucose.
The possible explanation for this dissonant observation may be
that, after mild STZ treatment, the diabetic rats were injected
with a minimum dose of exogenous insulin. Despite the fact that
no measurement of urine glucose was performed in the current
study, it has been reported that this type of treatment results in a
significant urinary glucose loss and polyurea (19,23). Further-
more, loss of glucose through the urine may result in hyper-
phagia, with the diabetic rats consuming food in excess to
compensate for these losses (24). Therefore, in order to precisely
determine the effects of GJG administration on blood glucose
levels in STZ-diabetes, mild food restriction would be required
in future studies. Incidentally, diet restriction and exercise ther-
apies are useful for improving insulin action (25,26), in order to
enhance the clinical benefits brought about by the treatment with
GJG; thus, self-control is very important for the diabetic patient.
STZ-diabetes leads to the development of insulin resistance
in hepatic and peripheral tissues (27,28). The hepatic glucose
production was reported to be inhibited by insulin in a dose-
dependent fashion (29) and was suppressed at 100  U/ml
insulin in the plasma (30). During the 6.0 mU/g/min insulin
infusion rate, insulin levels of about 100  U/ml were achieved.
Consequently, in our experiments, insulin-stimulated glucose
disposal under these conditions is mainly due to the reduced
glucose uptake in skeletal muscle. In other words, the results
of the present study suggest that GJG administration would
improve the insulin sensitivity in peripheral tissues (i.e., skele-
tal muscle). Previous studies have indicated that the vasodilat-
ing (14,15) and antinociceptive (16) effects of GJG, as well
as improvement in the platelet aggregation (31) and insulin
sensitivity (17), are connected with NO production. Moreover,
NO is an important endogenous vasodilator that mediates
various physiological functions, which may be associated with
increased rates of glucose metabolism in skeletal muscle
(32–34), and has an aldose reductase inhibition effect (35).
Additionally, decreased nitric oxide synthase (NOS) activation
could contribute to the genesis of many pathological condi-
tions such as diabetic vasculopathy and neuropathy (36,37).
Based on these evidences, we speculated that the pharmaco-
logical mechanism of GJG might be related to the NO path-
way, although we did not directly measure the effects of GJG
administration on the production of NO. Recent studies have
provided direct evidence for a complete biochemical pathway
involving the IR- , IRS-1 and PI 3-kinase that can account for
the important physiological actions of insulin in stimulating
the production of NO (32,33,38). Additionally, cinnamon
extract (a component herb of GJG) has been reported to poten-
tiate the in vivo insulin-regulated glucose utilization (20) and
to prevent the insulin resistance induced by a high-fructose
diet by enhancing insulin signaling (39). Therefore, we clari-
fied the effects of GJG administration on the initial steps of
the insulin-signaling cascade by analyzing skeletal muscle of
STZ-diabetes.
Previous studies have suggested that IRS-1 plays a central
role in the glucose transport in skeletal muscle and that
decreased expression of the IRS-1 protein is involved in the
development of insulin resistance (40–43). STZ-diabetes is
associated with large increases in insulin-stimulated IRS-1
tyrosine phosphorylation (8,9,18), despite the decreased levels
of total IRS-1 protein in skeletal muscle (8,18). Our results
showed that insulin combined with GJG treatment signifi-
cantly increases the amount of the IRS-1 protein (Fig. 5A) and
inhibits its increased tyrosine phosphorylation level more than
insulin alone. However, these levels did not reach those of the
controls (Fig. 5B). We also determined the upstream of IRS-1
in the insulin-signaling pathway: the protein content of IR- 
in the diabetic rats was significantly increased compared with
controls, and GJG administration did not affect the IR-  pro-
tein content. In contrast, the overexpressed tyrosine phosphor-
ylation levels of IR-  in STZ-diabetes were corrected by
insulin combined with GJG administration. The activation of
PI 3-kinase is required for insulin to stimulate glucose trans-
port (44,45). Although we have not assessed the effect on the
activation of PI 3-kinase, it was previously described that PI 
3-kinase activation closely correlates with IRS-1 phosphoryla-
tion in skeletal muscle of STZ-diabetes (46). The present data
revealed that insulin   GJG treatment inhibits the increased
IRS-1 tyrosine phosphorylation levels (Fig. 5B); therefore,
these improvements are thought to improve the abnormal
activation of PI 3-kinase (8,9) resulting in the correction of
decreased efficiency of glucose metabolization.
274 Insulin sensitivity and Kampo medicineOne of the characteristics of the Kampo medicine prescrip-
tion is that it is usually a mixture of individual crude herbs.
Although the main constituents and pharmacological proper-
ties (biological activities, toxicological aspects, etc.) of each
component herb of GJG have been detailed in previous reports
(2,20,39,47,48), the synergistic or synthetic effects between
individual herbs have not been fully understood. Some evi-
dences suggested that GJG could have multiple effects like
vasodilatation (14,15), aldose reductase inhibition (49), anti-
oxidant effect (50) and anti-nociceptive effect (16) owing to the
interactions between individual herbal components, and may
provide a wide range of therapeutic potential and utility (2).
This view is in agreement with our previous research (10–12,
17) and studies conducted by others (13,15). In summary,
based on these evidences, GJG may be a useful synthetic
traditional medicine prescription for the treatment of diabetic
neuropathy with multiple pathogenetic mechanisms.
The two noteworthy findings of this study were that, firstly,
GJG with or without a small dose of exogenous insulin pro-
duced a significant improvement in the insulin sensitivity in
STZ-diabetes and, secondly, the molecular effect of GJG prob-
ably occurred via correction of the abnormal early steps of the
insulin signaling pathway. Thus, correction of the abnormal
early step of insulin signaling in skeletal muscle of GJG-treated
STZ-diabetic rats may play an important role in improving
insulin sensitivity in vivo. In conclusion, the current study sug-
gests that long-term GJG administration would ameliorate the
insulin sensitivity, at least in part, by correcting the abnormal
insulin signaling in STZ-diabetes. However, further investiga-
tion on other molecular details regarding GJG is needed.
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